Pemazyre 13.5 mg tablets, Pemazyre 4.5 mg tablets, Pemazyre 9 mg tablets, Pemigatinib clinical trials

INCB 54828-801: An Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants With Advanced Malignancies Previously Enrolled in Studies of Pemigatinib

This study is for people with advanced cancer who are already taking a medicine called pemigatinib and are getting good results from it. It allows them to keep receiving this medicine if they can't get it elsewhere, helping doctors understand more about its long-term effects and safety.